01
Location:
Homepage
/
/
/
Teshin students make cancer no longer rampant

Teshin students make cancer no longer rampant

(Summary description)Text/ChaiYanCancerhaslongbeenseenasaworldwideproblem.Intheforeseeablefuturehopeforrecoveryanddecliningqualityoflife,oftenmakemanypatientsinthecancer"stalwarts"challenge.Evenifthetreatment,thetraditionalradiotherapy,chemotherapyinkillingtumorcells,toachievethesameeffect,becausethenormalcellsfromthejointresponse,thereisoftenalargetoxicsideeffects,topatientswithgreatpain.Allthismakescancertheunexpected,evenintherapiddevelopmentofmedicinetoday,formostpeople,ora"disaster".China'sentryintotheeraoftarg

Teshin students make cancer no longer rampant

(Summary description)Text/ChaiYanCancerhaslongbeenseenasaworldwideproblem.Intheforeseeablefuturehopeforrecoveryanddecliningqualityoflife,oftenmakemanypatientsinthecancer"stalwarts"challenge.Evenifthetreatment,thetraditionalradiotherapy,chemotherapyinkillingtumorcells,toachievethesameeffect,becausethenormalcellsfromthejointresponse,thereisoftenalargetoxicsideeffects,topatientswithgreatpain.Allthismakescancertheunexpected,evenintherapiddevelopmentofmedicinetoday,formostpeople,ora"disaster".China'sentryintotheeraoftarg

Information

Text / Chai Yan
    Cancer has long been seen as a worldwide problem. In the foreseeable future hope for recovery and declining quality of life, often make many patients in the cancer "stalwarts" challenge. Even if the treatment, the traditional radiotherapy, chemotherapy in killing tumor cells, to achieve the same effect, because the normal cells from the joint response, there is often a large toxic side effects, to patients with great pain. All this makes cancer the unexpected, even in the rapid development of medicine today, for most people, or a "disaster".
China's entry into the era of targeted therapy
    With the continuous development of cancer research, the gradual deepening of the understanding of the tumor, can be very confident that, through a reasonable combination of treatment, the treatment of many cancers has been able to be very satisfied. Many tumors, such as breast cancer, colorectal cancer, and so on, if they can be found early, the cure rate is very high.
And more and more widely used molecular target to treatment, due to specifically target cancer cells, let a patient to bid farewell to the traditional treatment of the past will bring great side effects, to prolong life and still get good quality of life, indeed serve multiple purposes. The president of the National Cancer Institute, said that if the cancer treatment was "looking for and damaging" in twenty-first Century, it was "targeting and control" in twentieth Century. It is no exaggeration to say that, as China gradually enters the era of targeted therapy, cancer can certainly become a chronic disease like high blood pressure.
New targeted therapy drugs continue to come out
    Molecular targeted therapy can control the change of gene expression by blocking the signal transduction pathways of tumor cells or related cells, which can inhibit or kill tumor cells. The biggest feature is to clearly identify tumor cell specific molecular targets, the use of drugs for the treatment of the target. Therefore, in effect at the same time, to avoid the damage to normal tissue, let the patient away from the fear of "kill with lawful authority". This also makes this kind of efficient, low adverse reaction of the treatment model, more and more doctors and the majority of patients with cancer. In clinic, the target to treat not only can single combat arms, and surgery, chemotherapy and radiotherapy combined with application, with a strong line-up of army type, annihilate the cancer cells.
    In recent years, a variety of targeted drugs frequently come out. In recent years, there have been a number of targeted therapies, such as monoclonal antibody therapy, gene therapy, targeted therapy of cell carrier and neovascularization.
Monoclonal antibody is the latest development direction
    The monoclonal antibody is produced in response to specific antigen specific monoclonal antibodies were purified. It has high specificity, can specificity for tumor cells to target to the treatment, from the molecular level in the reversal of tumor malignant biological behavior, so it is called "biological missile". This kind of medicine has the characteristics of strong targeting, high specificity and low side effects, and can enhance the therapeutic effect of radiotherapy and chemotherapy, which represents the latest development direction in the field of tumor therapy. In our country, this new type of monoclonal antibody (Tai Xinsheng) has also been published, because it can specifically attack the excessive expression of human epidermal growth factor receptor (EGFR) in tumor cells, and has been recognized." Liberation Army General Hospital, director of oncology, Shun Chang Jiao introduced professor, many tumors, such as head and neck cancer, non small cell lung cancer, colorectal cancer, pancreatic cancer, there are the over expression and if so, often lead to tumor continuous formation and deterioration. Therefore, when monoclonal antibody drug can block this process, it must be able to such as "missile like" tracking to kill cancer cells, and side reaction small, effectively extending survival of patients, improve the quality of life, has very high value in clinical application.
    At present, took a multi center clinical study in the United States, Chinese, Germany, Canada, Cuba is still. Teshin health combined with irinotecan and topotecan in the treatment of irinotecan for Kang resistant metastatic nodes in patients with rectal cancer, preliminary clinical study data are very encouraging, survival time of patients with extended further. And domestic teshin students combined with radiotherapy for nasopharyngeal carcinoma clinical trials showed, the complete remission rate as high as 90%, patients with improved survival, security good. Cuba teshin health combined with radiotherapy in the treatment of advanced head and neck cancer clinical study, the patients had a median survival time of 3.7 years. Compared with conventional treatment increased by more than 1 year. Because the teshin health outstanding achievement in advanced malignant glioma treatment, the drug by the U. S. Food and Drug Administration (FDA) and the food and Drug Administration dual certification, approved advanced glioma orphan drug designation, is expected to as a pediatric treatment advanced malignant glioma of line therapy.

搜索

Biotech pharmaceutical co., Ltd

Address:NO.2 Rongjing East Street, Beijing Economic and Technological Development Area, Beijing 100176

Biotech pharmaceutical co., Ltd  京ICP备05019954号 互联网药品信息编号:(京)非经营性2016-0046    www.300.cn